SlideShare a Scribd company logo
DIABETES MELLITUS,
MANAGEMENT BEYOND
THE NORMS IN
CHILDREN
Dr Oluwayemi Isaac Oludare
Consultant Paediatric Endocrinologist
Ekiti State University Teaching Hospital, Ado-Ekiti
MBBS, FWACP, FESPE
OUTLINE
 Introduction
 Epidemiology
 Classification
 Local experience
 Childhood Type 1 DM
 Childhood Type 2 DM
 Type1 vs Type 2 DM
 Maturity onset diabetes of the young (MODY)
 Management of Type 1 DM
 Insulin regimen
 Sick day rule
 Conclusion
WHAT IS DIABETES?
Diabetes mellitus is a group of
metabolic diseases characterized
by hyperglycemia resulting from
defects in insulin secretion, insulin
action or both.
INTRODUCTION
 DM: known to mankind since ancient times
 Diabetes means “flowing through”
 Mellitus means “sweet as honey”
 In the past DM was diagnosed by tasting the urine!
 Before insulin was discovered, type 1 DM always
resulted in death
 1st human treated with insulin: Leonard Thomson,
14yr/M, Canada, 1922
EPIDEMIOLOGY
 Number of people with DM varies in countries
 Worldwide, 430,000 children & adolescents aged ≤
14yrs have DM
 Each year, 77,000 children aged ≤ 14yrs and 119,000
aged ≥ 15yrs are found to have DM
 In the US, ≈ 13,000 new cases of DM are diagnosed in
children every year
 In EKSUTH, 1 new case/yr of DM diagnosed in
children(2010-2016), 5 in 2017, and 6 in 2018 (1 T2DM,
others T1DM);
 Finland has the highest incidence of childhood &
adolescent diabetes
 Childhood & adolescent type 1 DM is very uncommon in
Japan
 Reason for differences not known ?culture & environ
ESTIMATED WORLD PREVALENCE OF DIABETES
CLASSIFICATION
 Type 1 diabetes
 Autoimmune ß cell destruction causing absolute insulin
deficiency
 Type 2 diabetes
 Caused by either insulin resistance or due to secretory
defects of insulin
 Other types
 Genetic defects (e.g neonatal diabetes, MODY),
diseases of the pancreas, drug induced
LOCAL EXPERIENCE
age sex Year/ place
of
diagnosis
Type Therapy outcome
? 5
years
M 2009
EKSUTH
1 Insulin LAMA
9 years M 2011
LTH
Osogbo
1 Insulin Dead
2014
14 years M 2012
EKSUTH
1 Insulin LAMA
9 years F 2014
EKSUTH
1 Insulin Alive &
well
12 years F 2015
Private
hosp(LSH)
2 Metformin & Daonil Alive &
well
15 years M 2015
EKSUTH
1 Insulin Alive &
well
CHILDHOOD TYPE 1 DIABETES
 Accounts for 97% of childhood diabetes
 Incidence:
 40.2 per 100,000 in Finland (highest worldwide)
 15.7 – 17.6 per 100,000 in UK
 1.5 per 100,000 in Tanzania
 10.1 per 100,000 in Sudan
 20 per 100,000 in Morocco
 Prevalence:
 209 per 100,000 in England
 0.33 per 1000 in Nigeria
 0.95 per 1000 in Sudan
Incidence rising at 3.4% per year especially in under 5 yr
TYPE 1 DM, EPIDEMIOLOGY
 Age:
 Peak incidence between 10-14 years
 Sex:
 Slightly more common in boys
 Some studies in Nigeria, Ethiopia, Sudan, Libya have
suggested it to be more common in girls
 Race:
 More in Caucasians
 Season:
 More in winter
Insulin
Glucose production Lipolysis
Hyperglycemia fatty acids
Glycosuria Ketone bodies
Polyuria Acidosis
Thirsty
INSULIN
CLINICAL PRESENTATION
 DKA
 Most common mode of presentation in Africa (>85%)
 25% or less present with DKA in UK
 Presentation in DKA represents delayed diagnosis
 Other patients with type 1 DM will present with:
 Polyuria or secondary nocturnal enuresis
 Polydipsia
 Polyphagia
 Weight loss
 Lethargy
 Recurrent infection: candida
 DKA misdiagnosed as:
 Meningitis
 Cerebral malaria
 Pneumonia
 Mortality from DKA very high
(42.5% in Sudan)
DIAGNOSIS
 RBG > 11.1mmol/L if child has symptoms
 FBG > 7.0 mmol/L
 Plasma glucose > 11.1 mmol/L following an OGTT
 To reduce DKA in newly diagnosed children
 Refer on the basis of urinalysis or bedside RBG
 Refer by telephone on the day of suspicion
 Do not arrange FBG
CHILDHOOD TYPE 2 DM
 Only recognized in the last decade
 Previously thought to occur only in adults
 Prevalence:
 England: 3/ 100,000
 Japan: 13.5/ 100,000
 Taiwan: 15.9/ 100,000
 USA: 7.2/ 100,000
 UK: 0.53/ 100,000
CHILDREN AT RISK OF DEVELOPING TYPE 2 DM
 Obese
 Family history of type 2 DM
 Signs of insulin resistance
 Puberty
ACANTHOSIS NIGRICANS
NATURAL HISTORY OF TYPE 2 DM
Impaired Glucose Tolerance
Type 2 Diabetes
Normal Glucose tolerance
PROFILE OF SANDWELL CHILDREN WITH TYPE 2
DIABETES
• All obese
• Mean age at presentation : 12yrs
• 70% have acanthosis nigricans
• 53% of south Asian, 30% Caucasian, 7% Afro-Caribbean
• 84% Family history
• 30% persistent microalbuminuria
• 30% dyslipidaemia
LONG TERM OUTLOOK
• 14 times more risk of myocardial infarction
• In Canadian cohort of 51, by the age of 33 years:
4 had died
3 on dialysis
1 had toe amputated
1 was blind
Type 1 Type 2
Age of onset Any age Pubertal or older
Symptoms at onset DKA
Polyuria, polyphagia,
polydipsia, weight loss etc
Many are asymptomatic
but can present with 3P’s
etc. DKA rare but can
occur
BMI Normal but can be high Usually obese
Family History 2-4% 80%
Autoimmunity 85% isletcell/GAD
Thyroid dysfunction,
celiac disease associated
Not associated
TYPE 1 VS TYPE 2
Maturity onset diabetes of the
young (MODY)
• MODY describes dominantly inherited,
monogenic defects of insulin secretion
occurring at any age AND no longer
includes any forms of type 2 diabetes
• Many mutations identified
Clues to suspecting MODY
• Mild to moderate hyperglycemia (7-14 mmol/l)
discovered before 30 years of age.
• A first degree relative with a similar degree of
diabetes.
• Absence of positive antibodies or other
autoimmunity (e.g., thyroid disease) in patient
and family.
• Persistence of a low insulin requirement (e.g.,
less than 0.5 u/kg/day) past the usual
"honeymoon" period.
MANAGEMENT OF TYPE 1
DIABETES
 NICE guideline states that children and young
people should be offered ongoing integrated
Package of care by a Multidisciplinary Paediatric
Diabetes team.
 Team should consist of Consultant Paediatric
Diabetologist, dietician, Paediatric diabetic nurse,
Child Psychologist.
 Patients must have access to ophthalmology and
podiatry.
THERAPEUTIC GOALS FOR ALL CHILDREN
WITH DIABETES
Optimal metabolic Control
Normal physical development
Normal Psychosocial development
Optimal quality of Life
MANAGEMENT
 Initiate insulin treatment usually basal bolus.
 Dietetic advise
 Structured Education
 Ongoing surveillance, annual reviews
 Psychosocial support
 Transition
 24 hour Telephone contact
 Self management is the main principle of care
TARGETS
 HBA1c <7.5%
 Pre meal Blood glucose 4-8mmol/l
 Post meal BG Target less than 10mmol/l
 Healthy , well adjusted child
INSULIN REGIMENS
 Basal bolus
 Twice daily regimens
 Continuous subcutaneous insulin infusion (CSII)
Type of
insulin
examples Onset
of
action
Peak
action
duration
Rapid acting 1.Novorapid
2.Humalog
Lispro
10 mins 1-2 hrs 3-4 hrs
Short acting Actrapid 30 mins 2-3hrs 3-6hrs
Intermediate
acting
insulutard 2-4hrs 4-10hrs 10-16hrs
Long acting 1.Lantus
(Glargine)
2. Levemir
(Determir)
2-4 hrs No Peak 20-24hrs
INSULIN TYPES, & TIME OF ACTION
INSULIN REGIMENS
 Twice daily using pre-mixed or biphasic insulin e.g
-Mixtard 10, mixtard 20, mixtard 30
-Humulin M1, M2, M3, M4
-Novomix 30
-Humalog 25
TWICE DAILY REGIME
Starting dose: 0.5U/kg 2/3rd am, 1/3rd pm
Routine: meal times fixed
Meals: 3 main meals and 3 snacks
Insulin administered 30 mins before meals
Twice daily regimens
Target blood glucose is 4-8mmol/l in teens and 4-10mmol/l in
younger ones
Pre breakfast blood glucose reflect pre evening meal insulin dose
and vice versa
Use pattern recognition (3 DAYS ) to adjust insulin dose
SICK DAY RULES
 Never omit insulin
 Drink plenty of fluids
 More frequent blood sugar monitoring
 Check for ketones (e.g use of ß-ketone strips)
 Use of correction doses of short acting insulin
 Early contact with Diabetes team
MANAGEMENT (TYPE 2 DIABETES)
 Healthy eating and Regular exercise
 Drugs : Metformin, insulin
 Surveillance and treatment of complications
CONCLUSION
 Type 1 diabetes is the commonest type of
childhood diabetes
 Refer promptly by phone
 Childhood T2D is an emerging problem
 Transition to adult services needs to be
planned/improved
NO CHILD SHOULD DIE OF DIABETES!
In resuscitating diabetic patients
ABC should be followed by
Don’t
Ever
Forget
Glucose
THANK
YOU

More Related Content

Similar to Diabetes mellitus in children.pptx

diabetes mellitus presentation
diabetes mellitus presentationdiabetes mellitus presentation
diabetes mellitus presentation
NighatKanwal
 
Diabetes mellitus presentation
Diabetes mellitus presentationDiabetes mellitus presentation
Diabetes mellitus presentation
lakshmi das
 
Diabetes 1
Diabetes 1Diabetes 1
Diabetes 1
Sheetu Sharma
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
drankitguptamd
 
Diabetes Mellitus in Children - for UGs
Diabetes Mellitus in Children - for UGsDiabetes Mellitus in Children - for UGs
Diabetes Mellitus in Children - for UGs
CSN Vittal
 
DIABETES MELLITUS IN CHILDREN
DIABETES MELLITUS IN CHILDRENDIABETES MELLITUS IN CHILDREN
DIABETES MELLITUS IN CHILDREN
Arifa T N
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
Shine Thenu
 
Diabetes Mellitus
Diabetes Mellitus Diabetes Mellitus
Diabetes Mellitus
Vivek Kumar
 
Diabetic1
Diabetic1Diabetic1
Diabetic1
bausher willayat
 
Diabetes paediatrics
Diabetes paediatricsDiabetes paediatrics
Diabetes paediatrics
George Muli
 
Diabetes and oral health 2020
Diabetes and oral health 2020Diabetes and oral health 2020
Diabetes and oral health 2020
SamyAbdulHakiem
 
JDM.ppt
JDM.pptJDM.ppt
JDM.ppt
NikhilPT3
 
Pathology of Diabetes
Pathology of DiabetesPathology of Diabetes
Pathology of Diabetes
Shashidhar Venkatesh Murthy
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
Dr. Armaan Singh
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
Iqra Batool
 
Ueda2015 type 2 in children dr.alaa abdel-salam
Ueda2015 type 2 in children dr.alaa abdel-salamUeda2015 type 2 in children dr.alaa abdel-salam
Ueda2015 type 2 in children dr.alaa abdel-salam
ueda2015
 
Diabetes Mellitus Type 2 - Pathology.pptx
Diabetes Mellitus Type 2 - Pathology.pptxDiabetes Mellitus Type 2 - Pathology.pptx
Diabetes Mellitus Type 2 - Pathology.pptx
Jos University Teaching Hospital
 
Diabetes-no short of an epidemic!
Diabetes-no short of an epidemic!Diabetes-no short of an epidemic!
Diabetes-no short of an epidemic!
reliablerxpharmacy
 
Ueda 2016 6-diabetes in special populations - mesbah kamel
Ueda 2016 6-diabetes in special populations - mesbah kamelUeda 2016 6-diabetes in special populations - mesbah kamel
Ueda 2016 6-diabetes in special populations - mesbah kamel
ueda2015
 
Diabetes
Diabetes Diabetes
Diabetes
Balaji Thorat
 

Similar to Diabetes mellitus in children.pptx (20)

diabetes mellitus presentation
diabetes mellitus presentationdiabetes mellitus presentation
diabetes mellitus presentation
 
Diabetes mellitus presentation
Diabetes mellitus presentationDiabetes mellitus presentation
Diabetes mellitus presentation
 
Diabetes 1
Diabetes 1Diabetes 1
Diabetes 1
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes Mellitus in Children - for UGs
Diabetes Mellitus in Children - for UGsDiabetes Mellitus in Children - for UGs
Diabetes Mellitus in Children - for UGs
 
DIABETES MELLITUS IN CHILDREN
DIABETES MELLITUS IN CHILDRENDIABETES MELLITUS IN CHILDREN
DIABETES MELLITUS IN CHILDREN
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Diabetes Mellitus
Diabetes Mellitus Diabetes Mellitus
Diabetes Mellitus
 
Diabetic1
Diabetic1Diabetic1
Diabetic1
 
Diabetes paediatrics
Diabetes paediatricsDiabetes paediatrics
Diabetes paediatrics
 
Diabetes and oral health 2020
Diabetes and oral health 2020Diabetes and oral health 2020
Diabetes and oral health 2020
 
JDM.ppt
JDM.pptJDM.ppt
JDM.ppt
 
Pathology of Diabetes
Pathology of DiabetesPathology of Diabetes
Pathology of Diabetes
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Ueda2015 type 2 in children dr.alaa abdel-salam
Ueda2015 type 2 in children dr.alaa abdel-salamUeda2015 type 2 in children dr.alaa abdel-salam
Ueda2015 type 2 in children dr.alaa abdel-salam
 
Diabetes Mellitus Type 2 - Pathology.pptx
Diabetes Mellitus Type 2 - Pathology.pptxDiabetes Mellitus Type 2 - Pathology.pptx
Diabetes Mellitus Type 2 - Pathology.pptx
 
Diabetes-no short of an epidemic!
Diabetes-no short of an epidemic!Diabetes-no short of an epidemic!
Diabetes-no short of an epidemic!
 
Ueda 2016 6-diabetes in special populations - mesbah kamel
Ueda 2016 6-diabetes in special populations - mesbah kamelUeda 2016 6-diabetes in special populations - mesbah kamel
Ueda 2016 6-diabetes in special populations - mesbah kamel
 
Diabetes
Diabetes Diabetes
Diabetes
 

More from Kemi Adaramola

Renal Function Tests 2010.ppt
Renal Function Tests 2010.pptRenal Function Tests 2010.ppt
Renal Function Tests 2010.ppt
Kemi Adaramola
 
HYPOGLYCAEMIC AGENTS{ANTI DIABETIC DRUGS}2.ppt
HYPOGLYCAEMIC AGENTS{ANTI DIABETIC DRUGS}2.pptHYPOGLYCAEMIC AGENTS{ANTI DIABETIC DRUGS}2.ppt
HYPOGLYCAEMIC AGENTS{ANTI DIABETIC DRUGS}2.ppt
Kemi Adaramola
 
basic principles of ECHO.ppt
basic principles of ECHO.pptbasic principles of ECHO.ppt
basic principles of ECHO.ppt
Kemi Adaramola
 
DISEASES OF THE THYROID GLAND NOVEMBER 2018.pptx
DISEASES OF THE THYROID GLAND NOVEMBER  2018.pptxDISEASES OF THE THYROID GLAND NOVEMBER  2018.pptx
DISEASES OF THE THYROID GLAND NOVEMBER 2018.pptx
Kemi Adaramola
 
DEFIBRILLATION.pptx
DEFIBRILLATION.pptxDEFIBRILLATION.pptx
DEFIBRILLATION.pptx
Kemi Adaramola
 
PULMONARYHYPERTENSION IN HEART FAILURE.pptx
PULMONARYHYPERTENSION IN HEART FAILURE.pptxPULMONARYHYPERTENSION IN HEART FAILURE.pptx
PULMONARYHYPERTENSION IN HEART FAILURE.pptx
Kemi Adaramola
 
ADDISONIAN CRISIS 2.pptx
ADDISONIAN CRISIS 2.pptxADDISONIAN CRISIS 2.pptx
ADDISONIAN CRISIS 2.pptx
Kemi Adaramola
 
pulmo HTN.pptx
pulmo HTN.pptxpulmo HTN.pptx
pulmo HTN.pptx
Kemi Adaramola
 
NEW CARDIOVASCULAR RISK FACTORS.pptx
NEW CARDIOVASCULAR RISK FACTORS.pptxNEW CARDIOVASCULAR RISK FACTORS.pptx
NEW CARDIOVASCULAR RISK FACTORS.pptx
Kemi Adaramola
 
Management of ascites(3).pptx
Management of ascites(3).pptxManagement of ascites(3).pptx
Management of ascites(3).pptx
Kemi Adaramola
 
SUPPRATIVE LUNG DISEASES.pptx
SUPPRATIVE LUNG DISEASES.pptxSUPPRATIVE LUNG DISEASES.pptx
SUPPRATIVE LUNG DISEASES.pptx
Kemi Adaramola
 
Pyodermas by Essen .pptx
Pyodermas by Essen .pptxPyodermas by Essen .pptx
Pyodermas by Essen .pptx
Kemi Adaramola
 
ACUTE LEUKAEMIAS IN ADULTS.pptx
ACUTE LEUKAEMIAS IN ADULTS.pptxACUTE LEUKAEMIAS IN ADULTS.pptx
ACUTE LEUKAEMIAS IN ADULTS.pptx
Kemi Adaramola
 
blood and blood components therapy 1.ppt
blood and blood components therapy 1.pptblood and blood components therapy 1.ppt
blood and blood components therapy 1.ppt
Kemi Adaramola
 
Haemoglobinopathies npmc.ppt
Haemoglobinopathies npmc.pptHaemoglobinopathies npmc.ppt
Haemoglobinopathies npmc.ppt
Kemi Adaramola
 
Emerging and reemerging infections.ppt
Emerging and reemerging infections.pptEmerging and reemerging infections.ppt
Emerging and reemerging infections.ppt
Kemi Adaramola
 
PITUITARY DISORDERS.ppt
PITUITARY DISORDERS.pptPITUITARY DISORDERS.ppt
PITUITARY DISORDERS.ppt
Kemi Adaramola
 
Approach to stroke pt.pptx
Approach to stroke pt.pptxApproach to stroke pt.pptx
Approach to stroke pt.pptx
Kemi Adaramola
 
Addison's disease.ppt
Addison's disease.pptAddison's disease.ppt
Addison's disease.ppt
Kemi Adaramola
 
Alopecia by Essen .pptx
Alopecia by Essen .pptxAlopecia by Essen .pptx
Alopecia by Essen .pptx
Kemi Adaramola
 

More from Kemi Adaramola (20)

Renal Function Tests 2010.ppt
Renal Function Tests 2010.pptRenal Function Tests 2010.ppt
Renal Function Tests 2010.ppt
 
HYPOGLYCAEMIC AGENTS{ANTI DIABETIC DRUGS}2.ppt
HYPOGLYCAEMIC AGENTS{ANTI DIABETIC DRUGS}2.pptHYPOGLYCAEMIC AGENTS{ANTI DIABETIC DRUGS}2.ppt
HYPOGLYCAEMIC AGENTS{ANTI DIABETIC DRUGS}2.ppt
 
basic principles of ECHO.ppt
basic principles of ECHO.pptbasic principles of ECHO.ppt
basic principles of ECHO.ppt
 
DISEASES OF THE THYROID GLAND NOVEMBER 2018.pptx
DISEASES OF THE THYROID GLAND NOVEMBER  2018.pptxDISEASES OF THE THYROID GLAND NOVEMBER  2018.pptx
DISEASES OF THE THYROID GLAND NOVEMBER 2018.pptx
 
DEFIBRILLATION.pptx
DEFIBRILLATION.pptxDEFIBRILLATION.pptx
DEFIBRILLATION.pptx
 
PULMONARYHYPERTENSION IN HEART FAILURE.pptx
PULMONARYHYPERTENSION IN HEART FAILURE.pptxPULMONARYHYPERTENSION IN HEART FAILURE.pptx
PULMONARYHYPERTENSION IN HEART FAILURE.pptx
 
ADDISONIAN CRISIS 2.pptx
ADDISONIAN CRISIS 2.pptxADDISONIAN CRISIS 2.pptx
ADDISONIAN CRISIS 2.pptx
 
pulmo HTN.pptx
pulmo HTN.pptxpulmo HTN.pptx
pulmo HTN.pptx
 
NEW CARDIOVASCULAR RISK FACTORS.pptx
NEW CARDIOVASCULAR RISK FACTORS.pptxNEW CARDIOVASCULAR RISK FACTORS.pptx
NEW CARDIOVASCULAR RISK FACTORS.pptx
 
Management of ascites(3).pptx
Management of ascites(3).pptxManagement of ascites(3).pptx
Management of ascites(3).pptx
 
SUPPRATIVE LUNG DISEASES.pptx
SUPPRATIVE LUNG DISEASES.pptxSUPPRATIVE LUNG DISEASES.pptx
SUPPRATIVE LUNG DISEASES.pptx
 
Pyodermas by Essen .pptx
Pyodermas by Essen .pptxPyodermas by Essen .pptx
Pyodermas by Essen .pptx
 
ACUTE LEUKAEMIAS IN ADULTS.pptx
ACUTE LEUKAEMIAS IN ADULTS.pptxACUTE LEUKAEMIAS IN ADULTS.pptx
ACUTE LEUKAEMIAS IN ADULTS.pptx
 
blood and blood components therapy 1.ppt
blood and blood components therapy 1.pptblood and blood components therapy 1.ppt
blood and blood components therapy 1.ppt
 
Haemoglobinopathies npmc.ppt
Haemoglobinopathies npmc.pptHaemoglobinopathies npmc.ppt
Haemoglobinopathies npmc.ppt
 
Emerging and reemerging infections.ppt
Emerging and reemerging infections.pptEmerging and reemerging infections.ppt
Emerging and reemerging infections.ppt
 
PITUITARY DISORDERS.ppt
PITUITARY DISORDERS.pptPITUITARY DISORDERS.ppt
PITUITARY DISORDERS.ppt
 
Approach to stroke pt.pptx
Approach to stroke pt.pptxApproach to stroke pt.pptx
Approach to stroke pt.pptx
 
Addison's disease.ppt
Addison's disease.pptAddison's disease.ppt
Addison's disease.ppt
 
Alopecia by Essen .pptx
Alopecia by Essen .pptxAlopecia by Essen .pptx
Alopecia by Essen .pptx
 

Recently uploaded

Bringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured ApproachBringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured Approach
Brian Frerichs
 
The Power of Superfoods and Exercise.pdf
The Power of Superfoods and Exercise.pdfThe Power of Superfoods and Exercise.pdf
The Power of Superfoods and Exercise.pdf
Dr Rachana Gujar
 
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
nirahealhty
 
Luxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage CenterLuxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage Center
Chandrima Spa Ajman
 
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
rightmanforbloodline
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
priyabhojwani1200
 
Hypotension and role of physiotherapy in it
Hypotension and role of physiotherapy in itHypotension and role of physiotherapy in it
Hypotension and role of physiotherapy in it
Vishal kr Thakur
 
Vicarious movements or trick movements_AB.pdf
Vicarious movements or trick movements_AB.pdfVicarious movements or trick movements_AB.pdf
Vicarious movements or trick movements_AB.pdf
Arunima620542
 
FACIAL NERVE
FACIAL NERVEFACIAL NERVE
FACIAL NERVE
aditigupta1117
 
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdfMBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
bkling
 
GIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure andGIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure and
MuzafarBohio
 
Can Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdfCan Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdf
Dharma Homoeopathy
 
CCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer RehabpptxCCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer Rehabpptx
Canadian Cancer Survivor Network
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DR Jag Mohan Prajapati
 
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
Dinesh Chauhan
 
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGYTime line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
DianaRodriguez639773
 
Professional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine LectureProfessional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine Lecture
DIVYANSHU740006
 
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Levi Shapiro
 
PrudentRx: A Resource for Patient Education and Engagement
PrudentRx: A Resource for Patient Education and EngagementPrudentRx: A Resource for Patient Education and Engagement
PrudentRx: A Resource for Patient Education and Engagement
PrudentRx Program
 
Letter to MREC - application to conduct study
Letter to MREC - application to conduct studyLetter to MREC - application to conduct study
Letter to MREC - application to conduct study
Azreen Aj
 

Recently uploaded (20)

Bringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured ApproachBringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured Approach
 
The Power of Superfoods and Exercise.pdf
The Power of Superfoods and Exercise.pdfThe Power of Superfoods and Exercise.pdf
The Power of Superfoods and Exercise.pdf
 
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
 
Luxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage CenterLuxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage Center
 
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
 
Hypotension and role of physiotherapy in it
Hypotension and role of physiotherapy in itHypotension and role of physiotherapy in it
Hypotension and role of physiotherapy in it
 
Vicarious movements or trick movements_AB.pdf
Vicarious movements or trick movements_AB.pdfVicarious movements or trick movements_AB.pdf
Vicarious movements or trick movements_AB.pdf
 
FACIAL NERVE
FACIAL NERVEFACIAL NERVE
FACIAL NERVE
 
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdfMBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
 
GIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure andGIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure and
 
Can Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdfCan Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdf
 
CCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer RehabpptxCCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer Rehabpptx
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
 
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
 
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGYTime line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
 
Professional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine LectureProfessional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine Lecture
 
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
 
PrudentRx: A Resource for Patient Education and Engagement
PrudentRx: A Resource for Patient Education and EngagementPrudentRx: A Resource for Patient Education and Engagement
PrudentRx: A Resource for Patient Education and Engagement
 
Letter to MREC - application to conduct study
Letter to MREC - application to conduct studyLetter to MREC - application to conduct study
Letter to MREC - application to conduct study
 

Diabetes mellitus in children.pptx

  • 1. DIABETES MELLITUS, MANAGEMENT BEYOND THE NORMS IN CHILDREN Dr Oluwayemi Isaac Oludare Consultant Paediatric Endocrinologist Ekiti State University Teaching Hospital, Ado-Ekiti MBBS, FWACP, FESPE
  • 2. OUTLINE  Introduction  Epidemiology  Classification  Local experience  Childhood Type 1 DM  Childhood Type 2 DM  Type1 vs Type 2 DM  Maturity onset diabetes of the young (MODY)  Management of Type 1 DM  Insulin regimen  Sick day rule  Conclusion
  • 3. WHAT IS DIABETES? Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both.
  • 4. INTRODUCTION  DM: known to mankind since ancient times  Diabetes means “flowing through”  Mellitus means “sweet as honey”  In the past DM was diagnosed by tasting the urine!  Before insulin was discovered, type 1 DM always resulted in death  1st human treated with insulin: Leonard Thomson, 14yr/M, Canada, 1922
  • 5. EPIDEMIOLOGY  Number of people with DM varies in countries  Worldwide, 430,000 children & adolescents aged ≤ 14yrs have DM  Each year, 77,000 children aged ≤ 14yrs and 119,000 aged ≥ 15yrs are found to have DM  In the US, ≈ 13,000 new cases of DM are diagnosed in children every year  In EKSUTH, 1 new case/yr of DM diagnosed in children(2010-2016), 5 in 2017, and 6 in 2018 (1 T2DM, others T1DM);  Finland has the highest incidence of childhood & adolescent diabetes  Childhood & adolescent type 1 DM is very uncommon in Japan  Reason for differences not known ?culture & environ
  • 7.
  • 8. CLASSIFICATION  Type 1 diabetes  Autoimmune ß cell destruction causing absolute insulin deficiency  Type 2 diabetes  Caused by either insulin resistance or due to secretory defects of insulin  Other types  Genetic defects (e.g neonatal diabetes, MODY), diseases of the pancreas, drug induced
  • 9. LOCAL EXPERIENCE age sex Year/ place of diagnosis Type Therapy outcome ? 5 years M 2009 EKSUTH 1 Insulin LAMA 9 years M 2011 LTH Osogbo 1 Insulin Dead 2014 14 years M 2012 EKSUTH 1 Insulin LAMA 9 years F 2014 EKSUTH 1 Insulin Alive & well 12 years F 2015 Private hosp(LSH) 2 Metformin & Daonil Alive & well 15 years M 2015 EKSUTH 1 Insulin Alive & well
  • 10. CHILDHOOD TYPE 1 DIABETES  Accounts for 97% of childhood diabetes  Incidence:  40.2 per 100,000 in Finland (highest worldwide)  15.7 – 17.6 per 100,000 in UK  1.5 per 100,000 in Tanzania  10.1 per 100,000 in Sudan  20 per 100,000 in Morocco  Prevalence:  209 per 100,000 in England  0.33 per 1000 in Nigeria  0.95 per 1000 in Sudan Incidence rising at 3.4% per year especially in under 5 yr
  • 11. TYPE 1 DM, EPIDEMIOLOGY  Age:  Peak incidence between 10-14 years  Sex:  Slightly more common in boys  Some studies in Nigeria, Ethiopia, Sudan, Libya have suggested it to be more common in girls  Race:  More in Caucasians  Season:  More in winter
  • 12. Insulin Glucose production Lipolysis Hyperglycemia fatty acids Glycosuria Ketone bodies Polyuria Acidosis Thirsty INSULIN
  • 13. CLINICAL PRESENTATION  DKA  Most common mode of presentation in Africa (>85%)  25% or less present with DKA in UK  Presentation in DKA represents delayed diagnosis  Other patients with type 1 DM will present with:  Polyuria or secondary nocturnal enuresis  Polydipsia  Polyphagia  Weight loss  Lethargy  Recurrent infection: candida  DKA misdiagnosed as:  Meningitis  Cerebral malaria  Pneumonia  Mortality from DKA very high (42.5% in Sudan)
  • 14. DIAGNOSIS  RBG > 11.1mmol/L if child has symptoms  FBG > 7.0 mmol/L  Plasma glucose > 11.1 mmol/L following an OGTT  To reduce DKA in newly diagnosed children  Refer on the basis of urinalysis or bedside RBG  Refer by telephone on the day of suspicion  Do not arrange FBG
  • 15. CHILDHOOD TYPE 2 DM  Only recognized in the last decade  Previously thought to occur only in adults  Prevalence:  England: 3/ 100,000  Japan: 13.5/ 100,000  Taiwan: 15.9/ 100,000  USA: 7.2/ 100,000  UK: 0.53/ 100,000
  • 16. CHILDREN AT RISK OF DEVELOPING TYPE 2 DM  Obese  Family history of type 2 DM  Signs of insulin resistance  Puberty
  • 18. NATURAL HISTORY OF TYPE 2 DM Impaired Glucose Tolerance Type 2 Diabetes Normal Glucose tolerance
  • 19. PROFILE OF SANDWELL CHILDREN WITH TYPE 2 DIABETES • All obese • Mean age at presentation : 12yrs • 70% have acanthosis nigricans • 53% of south Asian, 30% Caucasian, 7% Afro-Caribbean • 84% Family history • 30% persistent microalbuminuria • 30% dyslipidaemia
  • 20. LONG TERM OUTLOOK • 14 times more risk of myocardial infarction • In Canadian cohort of 51, by the age of 33 years: 4 had died 3 on dialysis 1 had toe amputated 1 was blind
  • 21. Type 1 Type 2 Age of onset Any age Pubertal or older Symptoms at onset DKA Polyuria, polyphagia, polydipsia, weight loss etc Many are asymptomatic but can present with 3P’s etc. DKA rare but can occur BMI Normal but can be high Usually obese Family History 2-4% 80% Autoimmunity 85% isletcell/GAD Thyroid dysfunction, celiac disease associated Not associated TYPE 1 VS TYPE 2
  • 22. Maturity onset diabetes of the young (MODY) • MODY describes dominantly inherited, monogenic defects of insulin secretion occurring at any age AND no longer includes any forms of type 2 diabetes • Many mutations identified
  • 23. Clues to suspecting MODY • Mild to moderate hyperglycemia (7-14 mmol/l) discovered before 30 years of age. • A first degree relative with a similar degree of diabetes. • Absence of positive antibodies or other autoimmunity (e.g., thyroid disease) in patient and family. • Persistence of a low insulin requirement (e.g., less than 0.5 u/kg/day) past the usual "honeymoon" period.
  • 24. MANAGEMENT OF TYPE 1 DIABETES  NICE guideline states that children and young people should be offered ongoing integrated Package of care by a Multidisciplinary Paediatric Diabetes team.  Team should consist of Consultant Paediatric Diabetologist, dietician, Paediatric diabetic nurse, Child Psychologist.  Patients must have access to ophthalmology and podiatry.
  • 25.
  • 26. THERAPEUTIC GOALS FOR ALL CHILDREN WITH DIABETES Optimal metabolic Control Normal physical development Normal Psychosocial development Optimal quality of Life
  • 27. MANAGEMENT  Initiate insulin treatment usually basal bolus.  Dietetic advise  Structured Education  Ongoing surveillance, annual reviews  Psychosocial support  Transition  24 hour Telephone contact  Self management is the main principle of care
  • 28. TARGETS  HBA1c <7.5%  Pre meal Blood glucose 4-8mmol/l  Post meal BG Target less than 10mmol/l  Healthy , well adjusted child
  • 29. INSULIN REGIMENS  Basal bolus  Twice daily regimens  Continuous subcutaneous insulin infusion (CSII)
  • 30. Type of insulin examples Onset of action Peak action duration Rapid acting 1.Novorapid 2.Humalog Lispro 10 mins 1-2 hrs 3-4 hrs Short acting Actrapid 30 mins 2-3hrs 3-6hrs Intermediate acting insulutard 2-4hrs 4-10hrs 10-16hrs Long acting 1.Lantus (Glargine) 2. Levemir (Determir) 2-4 hrs No Peak 20-24hrs INSULIN TYPES, & TIME OF ACTION
  • 31. INSULIN REGIMENS  Twice daily using pre-mixed or biphasic insulin e.g -Mixtard 10, mixtard 20, mixtard 30 -Humulin M1, M2, M3, M4 -Novomix 30 -Humalog 25
  • 32. TWICE DAILY REGIME Starting dose: 0.5U/kg 2/3rd am, 1/3rd pm Routine: meal times fixed Meals: 3 main meals and 3 snacks Insulin administered 30 mins before meals
  • 33. Twice daily regimens Target blood glucose is 4-8mmol/l in teens and 4-10mmol/l in younger ones Pre breakfast blood glucose reflect pre evening meal insulin dose and vice versa Use pattern recognition (3 DAYS ) to adjust insulin dose
  • 34. SICK DAY RULES  Never omit insulin  Drink plenty of fluids  More frequent blood sugar monitoring  Check for ketones (e.g use of ß-ketone strips)  Use of correction doses of short acting insulin  Early contact with Diabetes team
  • 35. MANAGEMENT (TYPE 2 DIABETES)  Healthy eating and Regular exercise  Drugs : Metformin, insulin  Surveillance and treatment of complications
  • 36. CONCLUSION  Type 1 diabetes is the commonest type of childhood diabetes  Refer promptly by phone  Childhood T2D is an emerging problem  Transition to adult services needs to be planned/improved
  • 37. NO CHILD SHOULD DIE OF DIABETES! In resuscitating diabetic patients ABC should be followed by Don’t Ever Forget Glucose

Editor's Notes

  1. Sandwell is a metropolitan borough in the West Mainlands of England
  2. NICE: National Institute for Health and Clinical Excellence
  3. CSII uses a small battery powered syringe driver or insulin pump and a short acting insulin (or insulin analogue). The pump is worn 24 hours a day and insulin delivered via a subcutaneous needle sited in the abdominal wall or thigh. The pump hold sufficient insulin for 2 to 3 daysafter which the pump is refilled and he subcutaneous needle resited. The pump can be programmed to infuse insulin continuously